{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:24:01Z","timestamp":1788837841394,"version":"build-2803163510"},"reference-count":98,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005410","name":"American-Italian Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA211024"],"award-info":[{"award-number":["P50CA211024"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA265768"],"award-info":[{"award-number":["P01CA265768"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["DoD PC160357"],"award-info":[{"award-number":["DoD PC160357"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100027747","name":"America-Israel Cultural Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100027747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020424","name":"Weill Cornell Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020424","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgpath.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Pathology Clinics"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.path.2024.10.003","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T07:52:18Z","timestamp":1732866738000},"page":"25-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Deciphering Complexity"],"prefix":"10.1016","volume":"18","author":[{"given":"Giuseppe Nicol\u00f2","family":"Fanelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Vitale","family":"Nuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pederzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Loda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.path.2024.10.003_bib1","first-page":"17","article-title":"Cancer statistics, 2023. Article","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.path.2024.10.003_bib2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines(R) insights: prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"10305","key":"10.1016\/j.path.2024.10.003_bib3","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.path.2024.10.003_bib4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","article-title":"Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification","volume":"27","author":"Shore","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.path.2024.10.003_bib5","first-page":"977","article-title":"Systematic literature review of the epidemiology of advanced prostate cancer and associated homologous recombination repair gene alterations","volume":"205","author":"Shore","year":"2021","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.path.2024.10.003_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.urology.2016.06.011","article-title":"Predictors of time to metastasis in castration-resistant prostate cancer","volume":"96","author":"Moreira","year":"2016","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.path.2024.10.003_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.euf.2019.01.016","article-title":"Biological evolution of castration-resistant prostate cancer","volume":"5","author":"Davies","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"11","key":"10.1016\/j.path.2024.10.003_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41585-019-0237-8","article-title":"Towards precision oncology in advanced prostate cancer","volume":"16","author":"Ku","year":"2019","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.path.2024.10.003_bib9","first-page":"433","article-title":"Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing","volume":"174","author":"Viswanathan","year":"2018","journal-title":"Article. Cell"},{"issue":"3","key":"10.1016\/j.path.2024.10.003_bib10","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","article-title":"Genomic hallmarks and structural variation in metastatic prostate cancer","volume":"174","author":"Quigley","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.path.2024.10.003_bib11","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.path.2024.10.003_bib12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2018.05.037","article-title":"A\u00a0somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer. article","volume":"174","author":"Takeda","year":"2018","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.path.2024.10.003_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15205047","article-title":"Castration-resistant prostate cancer: from uncovered resistance mechanisms to current treatments","volume":"15","author":"Le","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.path.2024.10.003_bib14","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1038\/s41467-019-13084-7","article-title":"The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact","volume":"10","author":"van Dessel","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.path.2024.10.003_bib15","doi-asserted-by":"crossref","first-page":"878","DOI":"10.15252\/emmm.201303701","article-title":"Targeting the adaptive molecular landscape of castration-resistant prostate cancer","volume":"7","author":"Wyatt","year":"2015","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.path.2024.10.003_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrurol.2014.345","article-title":"Switching and withdrawing hormonal agents for castration-resistant prostate cancer. Review","volume":"12","author":"Lorente","year":"2015","journal-title":"Nat Rev Urol"},{"issue":"9","key":"10.1016\/j.path.2024.10.003_bib17","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","article-title":"An F876l mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (Enzalutamide). Article","volume":"3","author":"Korpal","year":"2013","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.path.2024.10.003_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41391-020-00308-x","article-title":"Clinical implications of genomic alterations in metastatic prostate cancer","volume":"24","author":"Sumiyoshi","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"10.1016\/j.path.2024.10.003_bib19","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ctrv.2015.05.003","article-title":"The hallmarks of castration-resistant prostate cancers","volume":"41","author":"Katsogiannou","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.path.2024.10.003_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112563","article-title":"AR splicing variants and resistance to AR targeting agents","volume":"13","author":"Kanayama","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.path.2024.10.003_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13668","article-title":"Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Article","author":"Henzler","year":"2016","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.path.2024.10.003_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ajur.2020.01.001","article-title":"Regulation of androgen receptor variants in prostate cancer. Review","volume":"7","author":"Zhu","year":"2020","journal-title":"Asian J Urol"},{"issue":"3","key":"10.1016\/j.path.2024.10.003_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41391-020-0217-3","article-title":"Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. Review","volume":"23","author":"Lu","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"17","key":"10.1016\/j.path.2024.10.003_bib24","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1158\/0008-5472.CAN-15-0381","article-title":"Androgen receptor splice variants dimerize to transactivate target genes. Article","volume":"75","author":"Xu","year":"2015","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.path.2024.10.003_bib25","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.18632\/oncotarget.1802","article-title":"Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Article","volume":"5","author":"Cao","year":"2014","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.path.2024.10.003_bib26","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1172\/JCI41824","article-title":"Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. Article","volume":"120","author":"Sun","year":"2010","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.path.2024.10.003_bib27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1158\/1541-7786.MCR-16-0236","article-title":"Interplay between cytoplasmic and nuclear androgen receptor splice variants mediates castration resistance. Article","volume":"15","author":"Zhan","year":"2017","journal-title":"Mol Cancer Res"},{"issue":"15","key":"10.1016\/j.path.2024.10.003_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24152783","article-title":"A\u00a0structure-activity relationship study of bis-benzamides as inhibitors of androgen receptor-coactivator interaction","volume":"24","author":"Lee","year":"2019","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.path.2024.10.003_bib29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrurol.2011.67","article-title":"Targeting \u03b1-reductase for prostate cancer prevention and treatment. Review","volume":"8","author":"Nacusi","year":"2011","journal-title":"Nat Rev Urol"},{"issue":"10","key":"10.1016\/j.path.2024.10.003_bib30","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.bbalip.2013.03.010","article-title":"The fat side of prostate cancer. Review","volume":"1831","author":"Zadra","year":"2013","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"5350","key":"10.1016\/j.path.2024.10.003_bib31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.279.5350.563","article-title":"Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study","volume":"279","author":"Chan","year":"1998","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.path.2024.10.003_bib32","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/jnci\/92.23.1918","article-title":"Her-2-neu expression and progression toward androgen independence in human prostate cancer","volume":"92","author":"Signoretti","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.path.2024.10.003_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","article-title":"Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer. article","volume":"76","author":"Hamid","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.path.2024.10.003_bib34","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.euf.2017.03.004","article-title":"PTEN Loss but Not ERG expression in diagnostic biopsies is associated with increased risk of progression and adverse surgical findings in men with prostate cancer on active surveillance. article","volume":"4","author":"Lokman","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"3","key":"10.1016\/j.path.2024.10.003_bib35","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized phase II study evaluating AKT blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss. Article","volume":"25","author":"De Bono","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.path.2024.10.003_bib36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-18-2068","article-title":"Rb1 heterogeneity in advanced metastatic castration-resistant prostate cancer. Article","volume":"25","author":"Rodrigues","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.path.2024.10.003_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.5573","article-title":"Clinical outcomes and markers of treatment response in a randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-intact metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"38","author":"Palmbos","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.path.2024.10.003_bib38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.2018.36.6_suppl.57","article-title":"P53 as a predictor of clinical outcome in localized prostate cancer","volume":"36","author":"Mahon","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.path.2024.10.003_bib39","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Cancer Genome Atlas Research","year":"2015","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.path.2024.10.003_bib40","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.ccell.2018.10.016","article-title":"Molecular evolution of early-onset prostate cancer identifies molecular risk markers and clinical trajectories","volume":"34","author":"Gerhauser","year":"2018","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.path.2024.10.003_bib41","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.path.2024.10.003_bib42","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1530\/ERC-19-0420","article-title":"The epigenetic and transcriptional landscape of neuroendocrine prostate cancer","volume":"27","author":"Davies","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.path.2024.10.003_bib43","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41416-020-01114-x","article-title":"Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer","volume":"124","author":"Lozano","year":"2021","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.path.2024.10.003_bib44","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"Prorepair-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. Article","volume":"37","author":"Castro","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.path.2024.10.003_bib45","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer. Article","volume":"375","author":"Pritchard","year":"2016","journal-title":"New Engl J Med"},{"issue":"13","key":"10.1016\/j.path.2024.10.003_bib46","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1002\/cncr.32908","article-title":"Germline and somatic DNA repair gene alterations in prostate cancer","volume":"126","author":"Dall'Era","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.path.2024.10.003_bib47","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 Delineates a distinct Immunogenic Class of advanced prostate cancer. Article","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.path.2024.10.003_bib48","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","article-title":"Synthetic lethal therapies for cancer: what\u2019s next after PARP inhibitors? Review","volume":"15","author":"Ashworth","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.path.2024.10.003_bib49","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers. Article","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.path.2024.10.003_bib50","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression. Article","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.path.2024.10.003_bib51","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1158\/1078-0432.CCR-19-1623","article-title":"Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer. Article","volume":"26","author":"Ritch","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.path.2024.10.003_bib52","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. article","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.path.2024.10.003_bib53","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.2217\/fon-2019-0068","article-title":"Clinical implications of mismatch repair deficiency in prostate cancer","volume":"15","author":"Sedhom","year":"2019","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.path.2024.10.003_bib54","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2018.10.009","article-title":"Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. article","volume":"75","author":"Antonarakis","year":"2019","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.path.2024.10.003_bib55","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Article","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.path.2024.10.003_bib56","article-title":"Guidelines for genetic testing in prostate cancer: a scoping review","author":"Tuffaha","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"10.1016\/j.path.2024.10.003_bib57","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","article-title":"Molecular events in neuroendocrine prostate cancer development. Review","volume":"18","author":"Wang","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.path.2024.10.003_bib58","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fonc.2020.00569","article-title":"Recent advances in cancer plasticity: cellular mechanisms, surveillance strategies, and therapeutic optimization","volume":"10","author":"Fanelli","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.path.2024.10.003_bib59","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Article","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.path.2024.10.003_bib60","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-High SCLC: results from the phase 3 TAHOE study. article","volume":"16","author":"Blackhall","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"5","key":"10.1016\/j.path.2024.10.003_bib61","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11912-017-0593-6","article-title":"Emerging variants of castration-resistant prostate cancer","volume":"19","author":"Vlachostergios","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"10.1016\/j.path.2024.10.003_bib62","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.path.2024.10.003_bib63","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"23","key":"10.1016\/j.path.2024.10.003_bib64","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance. Review","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6320","key":"10.1016\/j.path.2024.10.003_bib65","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.path.2024.10.003_bib66","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1038\/s41467-021-23780-y","article-title":"Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer","volume":"12","author":"Brady","year":"2021","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.path.2024.10.003_bib67","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1158\/0008-5472.CAN-21-2352","article-title":"Pyruvate kinase M1 suppresses development and progression of prostate adenocarcinoma","volume":"82","author":"Davidson","year":"2022","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.path.2024.10.003_bib68","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41467-023-44210-1","article-title":"Distinct mesenchymal cell states mediate prostate cancer progression","volume":"15","author":"Pakula","year":"2024","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.path.2024.10.003_bib69","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/bco2.212","article-title":"Genomic alterations in neuroendocrine prostate cancer: a systematic review and meta-analysis","volume":"4","author":"Chen","year":"2023","journal-title":"BJUI Compass"},{"issue":"6","key":"10.1016\/j.path.2024.10.003_bib70","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Article","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.path.2024.10.003_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241813673","article-title":"Targeting key players of neuroendocrine differentiation in prostate cancer","volume":"24","author":"Zamora","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.path.2024.10.003_bib72","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","article-title":"N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells","volume":"29","author":"Lee","year":"2016","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.path.2024.10.003_bib73","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","article-title":"N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. article","volume":"30","author":"Dardenne","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.path.2024.10.003_bib74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-020-01305-3","article-title":"Targeting AURKA in cancer: molecular mechanisms and opportunities for Cancer therapy. Review","volume":"20","author":"Du","year":"2021","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.path.2024.10.003_bib75","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ccr.2013.05.005","article-title":"Small molecule inhibitors of aurora-a induce proteasomal degradation of N-Myc in childhood neuroblastoma. Article","volume":"24","author":"Brockmann","year":"2013","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.path.2024.10.003_bib76","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912","article-title":"A\u00a0phase II trial of the aurora kinase a inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers. Article","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.path.2024.10.003_bib77","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/pros.23715","article-title":"SRRM4 gene expression correlates with neuroendocrine prostate cancer. Article","volume":"79","author":"Li","year":"2019","journal-title":"Prostate"},{"issue":"28","key":"10.1016\/j.path.2024.10.003_bib78","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1038\/onc.2017.50","article-title":"FOXA1 inhibits prostate cancer neuroendocrine differentiation. Article","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.path.2024.10.003_bib79","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","article-title":"The master neural transcription factor BRN2 is an androgen receptor\u2013suppressed driver of neuroendocrine differentiation in prostate cancer. Article","volume":"7","author":"Bishop","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.path.2024.10.003_bib80","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1002\/jcp.29267","article-title":"Elevating SOX2 in prostate tumor cells upregulates expression of neuroendocrine genes, but does not reduce the inhibitory effects of enzalutamide. Article","volume":"235","author":"Metz","year":"2020","journal-title":"J\u00a0Cell Physiol"},{"issue":"1","key":"10.1016\/j.path.2024.10.003_bib81","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1530\/JME-18-0226","article-title":"PEG10 is associated with treatment-induced neuroendocrine prostate cancer. Article","volume":"63","author":"Kim","year":"2019","journal-title":"J\u00a0Mol Endocrinol"},{"issue":"1","key":"10.1016\/j.path.2024.10.003_bib82","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41467-018-08133-6","article-title":"ONECUT2 is a driver of neuroendocrine prostate cancer. Article","volume":"10","author":"Guo","year":"2019","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.path.2024.10.003_bib83","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41591-018-0241-1","article-title":"ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Article","volume":"24","author":"Rotinen","year":"2018","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.path.2024.10.003_bib84","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1158\/0008-5472.CAN-17-3677","article-title":"Heterochromatin protein 1a mediates development and aggressiveness of neuroendocrine prostate cancer. Article","volume":"78","author":"Ci","year":"2018","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.path.2024.10.003_bib85","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1172\/JCI132031","article-title":"Genomics of lethal prostate cancer at diagnosis and castration resistance. Article","volume":"130","author":"Mateo","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"10.1016\/j.path.2024.10.003_bib86","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41585-020-0297-9","article-title":"Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Review","volume":"17","author":"Maia","year":"2020","journal-title":"Nat Rev Urol"},{"issue":"18","key":"10.1016\/j.path.2024.10.003_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184359","article-title":"Circulating cell-free DNA in renal cell carcinoma: the new era of precision medicine","volume":"14","author":"Francini","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.path.2024.10.003_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16030662","article-title":"Cell-Free DNA: unveiling the future of cancer diagnostics and monitoring","volume":"16","author":"Francini","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.path.2024.10.003_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103963","article-title":"Standard operating procedures (SOPs) for non-invasive multiple biomarkers detection in an academic setting: a critical review of the literature for the RENOVATE study protocol","volume":"185","author":"Dameri","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"19","key":"10.1016\/j.path.2024.10.003_bib90","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Article","volume":"14","author":"De Bono","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.path.2024.10.003_bib91","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.2017.75.2998","article-title":"Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase III clinical trials. Conference Paper","volume":"36","author":"Heller","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"831","key":"10.1016\/j.path.2024.10.003_bib92","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.adh1922","article-title":"Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused by PARP inhibition","volume":"17","author":"Ribeiro","year":"2024","journal-title":"Sci Signal"},{"issue":"6","key":"10.1016\/j.path.2024.10.003_bib93","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s41416-022-02085-x","article-title":"Stromal cells in prostate cancer pathobiology: friends or foes?","volume":"128","author":"Pederzoli","year":"2023","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.path.2024.10.003_bib94","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/1541-7786.MCR-20-0548","article-title":"Metabolomics of prostate cancer gleason score in tumor tissue and serum","volume":"19","author":"Penney","year":"2021","journal-title":"Mol Cancer Res"},{"issue":"21","key":"10.1016\/j.path.2024.10.003_bib98","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.3390\/cancers16213685","article-title":"Deciphering the tumor microenvironment in prostate cancer: a focus on the stromal component","volume":"16","author":"Pakula","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.path.2024.10.003_bib95","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41467-017-00460-4","article-title":"Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer","volume":"8","author":"Tyekucheva","year":"2017","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.path.2024.10.003_bib96","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1158\/1541-7786.MCR-22-0627","article-title":"The prostate stromal transcriptome in aggressive and lethal prostate cancer","volume":"21","author":"Ma","year":"2023","journal-title":"Mol Cancer Res"},{"issue":"12","key":"10.1016\/j.path.2024.10.003_bib97","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/j.1464-410X.2008.08255.x","article-title":"Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study","volume":"103","author":"Kvale","year":"2009","journal-title":"BJU Int"}],"container-title":["Surgical Pathology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918124000801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918124000801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:32:54Z","timestamp":1760074374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875918124000801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1875918124000801"],"URL":"https:\/\/doi.org\/10.1016\/j.path.2024.10.003","relation":{},"ISSN":["1875-9181"],"issn-type":[{"value":"1875-9181","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deciphering Complexity","name":"articletitle","label":"Article Title"},{"value":"Surgical Pathology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.path.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}